The two first surgeries with Episurf Medical´s third product, the Episealer® Twin, were conducted by the orthopaedic surgeon, Dr. Johannes Holz, at OrthoCentrum in Hamburg, Germany. The procedures went according to plan for both patients, a 52 year old woman and a 51 year old man, who both had undergone two previously failed biological treatments prior to getting the implant.
This information was published, 2015-10-08 14:38 CEST (GLOBE NEWSWIRE) --
The Episealer® Twin is a patient specific resurfacing implant intended for the treatment of patients who have elongated cartilage defects and underlying bone damage in the condyles and trochlea area.
Assisting during both surgeries was Professor Leif Ryd, Senior Medical Advisor at Episurf Medical. “The implantation worked very satisfactory on both patients, the tools and the customized devices fitted perfectly. The post surgical x-rays showed a perfect aligned implant, congruent to the surrounding native cartilage”, says Dr. Johannes Holz, Head of the Department for Orthopaedic Surgery and Sports Medicine.
Prior to the surgery, the first patient had a history of suffering from pain for more than three decades and reduced functionality which was getting worse over time. After the surgery, the patient had a rapid recovery with an instant range of motion of 0-90 – meaning this patient has 90 degree flexion and full extension.
“Our goal is to delay conventional joint replacement in mid aged patients. In the aim of partial resurfacing, the Episealer implants are positioned in my work between biological resurfacing and uni arthroplasty, making a less invasive treatment possible for patients when biological treatment has failed. The individual inlay joint surface restoration allows joint preservation; this leads to minimal removal of bone stock and a conservation of healthy cartilage and is one of my treatment options in unicompartmental osteoarthritis”, says Dr. Johannes Holz, Episurf Medical has three patient specific products on the market, which complement each other and allow the company to meet the increasing need for treating different types of lesions in knee joints.
“Both implants were pre-ordered in anticipation of receiving the CE-mark which is a clear sign of the market demand for the Episealer® Twin. This is a great complement to our portfolio enabling the treatment of patients who have elongated or multiple lesions. We are also pleased that the new product is gaining early traction in Germany, one of our key European markets”, says Rosemary Cunningham Thomas, CEO, Episurf Medical.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
Published at Globe Newswire